B-cell receptor signaling as a driver of lymphoma development and evolution

Seminars in Cancer Biology

Volumn 23, Issue 6 Part A, 2013, Pages 410-421

  Niemann, Carsten U ^a   Wiestner, Adrian ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

Antigen; B cell receptor; Ibrutinib; Idelalisib; Lymphoma

Indexed keywords

ANTINEOPLASTIC AGENT; AVL 292; B LYMPHOCYTE RECEPTOR; BENDAMUSTINE; BORTEZOMIB; BRUTON TYROSINE KINASE; BUPARLISIB; CHLORAMBUCIL; FLUDARABINE; IBRUTINIB; IDELALISIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; OFATUMUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE LYN; PROTEIN KINASE SYK; RIGOSERTIB; RITUXIMAB; UNCLASSIFIED DRUG; XL 147;

ANEMIA; B CELL LYMPHOMA; B LYMPHOCYTE; BURKITT LYMPHOMA; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL EFFECTIVENESS; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME PHOSPHORYLATION; FEBRILE NEUTROPENIA; HUMAN; HYPERTRANSAMINASEMIA; LARGE CELL LYMPHOMA; LYMPHOCYTE FUNCTION; LYMPHOMA; MAINTENANCE THERAPY; MANTLE CELL LYMPHOMA; MOLECULAR EVOLUTION; MOLECULAR PATHOLOGY; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; NONHUMAN; PNEUMONIA; PROGRESSION FREE SURVIVAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; SURVIVAL RATE; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; WALDENSTROEM MACROGLOBULINEMIA;

ANTIGEN; B-CELL RECEPTOR; IBRUTINIB; IDELALISIB; LYMPHOMA;

ANTIGENS, CD79; B-LYMPHOCYTES; CARD SIGNALING ADAPTOR PROTEINS; ENZYME INHIBITORS; GUANYLATE CYCLASE; HUMANS; LYMPHOMA; MOLECULAR TARGETED THERAPY; MUTATION; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN-TYROSINE KINASES; RECEPTORS, ANTIGEN, B-CELL; SIGNAL TRANSDUCTION;

EID: 84887613770     PISSN: 1044579X     EISSN: 10963650     Source Type: Journal    
DOI: 10.1016/j.semcancer.2013.09.001     Document Type: Review

References (170)

1. Young R.M., Staudt L.M. Targeting pathological B cell receptor signalling in lymphoid malignancies. Nat Rev Drug Discov 2013, 12(March (3)):229-243.
2. Stevenson F.K., Krysov S., Davies A.J., Steele A.J., Packham G. B-cell receptor signaling in chronic lymphocytic leukemia. Blood 2011, 118(October (16)):4313-4320.
3. Wiestner A. Targeting B-Cell receptor signaling for anticancer therapy: the Bruton's tyrosine kinase inhibitor ibrutinib induces impressive responses in B-cell malignancies. J Clin Oncol 2013, 31(January (1)):128-130.
4. Woyach J.A., Johnson A.J., Byrd J.C. The B-cell receptor signaling pathway as a therapeutic target in CLL. Blood 2012, 120(August (6)):1175-1184.
5. Davids M.S., Brown J.R. Targeting the B cell receptor pathway in chronic lymphocytic leukemia. Leukemia Lymphoma 2012, 53(December (12)):2362-2370.
6. Quinn E.R., Chan C.H., Hadlock K.G., Foung S.K., Flint M., Levy S. The B-cell receptor of a hepatitis C virus (HCV)-associated non-Hodgkin lymphoma binds the viral E2 envelope protein, implicating HCV in lymphomagenesis. Blood 2001, 98(December (13)):3745-3749.
7. Hermine O., Lefrere F., Bronowicki J.P., Mariette X., Jondeau K., Eclache-Saudreau V., et al. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med 2002, 347(July (2)):89-94.
8. Sachen K.L., Strohman M.J., Singletary J., Alizadeh A.A., Kattah N.H., Lossos C., et al. Self-antigen recognition by follicular lymphoma B-cell receptors. Blood 2012, 120(November (20)):4182-4190.
9. Duhren-von M.M., Ubelhart R., Schneider D., Wossning T., Bach M.P., Buchner M., et al. Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling. Nature 2012, 489(September (7415)):309-312.
10. Zwick C., Fadle N., Regitz E., Kemele M., Stilgenbauer S., Buhler A., et al. Autoantigenic targets of B-cell receptors derived from chronic lymphocytic leukemias bind to and induce proliferation of leukemic cells. Blood 2013, 121(June (23)):4708-4717.
11. Agathangelidis A., Darzentas N., Hadzidimitriou A., Brochet X., Murray F., Yan X.J., et al. Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapies. Blood 2012, 119(May (19)):4467-4475.
12. Lenz G., Davis R.E., Ngo V.N., Lam L., George T.C., Wright G.W., et al. Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science 2008, 319(March (5870)):1676-1679.
13. Friedberg J.W., Sharman J., Sweetenham J., Johnston P.B., Vose J.M., Lacasce A., et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 2010, 115(April (13)):2578-2585.
14. Advani R.H., Buggy J.J., Sharman J.P., Smith S.M., Boyd T.E., Grant B., et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol 2012, October.
15. Wang M., Rule S.A., Martin P., Goy A., Auer R., Kahl B.S., et al. Interim results of an international, multicenter, phase 2 study of Bruton's tyrosine kinase (btk) inhibitor, ibrutinib (PCI-32765), in relapsed or refractory mantle cell lymphoma (MCL): durable efficacy and tolerability with longer follow-up. ASH Annual Meeting Abstracts 2012, 120(November (21)):904.
16. Staudt L.M., Dunleavy K., Buggy J.J., Hedrick E., Lucas N., Pittaluga S., et al. The Bruton's tyrosine kinase (Btk) inhibitor PCI-32765 modulates chronic active BCR signaling and induces tumor regression in relapsed/refractory ABC DLBCL. ASH Annual Meeting Abstracts 2011, 118(November (21)):2716.
17. Farooqui M., Aue G., Valdez J., Saba N., Herman S.E.M., Lipsky A., et al. Rapid decrease in overall tumor burden on ibrutinib (PCI-32765) in CLL despite transient increase in ALC indicates a significant degree of treatment induced cell death. ASH Annual Meeting Abstracts 2012, 120(November (21)):2899.
18. Byrd J.C., Furman R.R., Coutre S.E., Flinn I.W., Burger J.A., Blum K.A., et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 2013, 369(July (1)):32-42.
19. Coutre S.E., Byrd J.C., Furman R.R., Brown J.R., Benson D.M., Wagner-Johnston N.D., et al. Phase I study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110d, in patients with previously treated chronic lymphocytic leukemia. ASCO Meeting Abstracts 2011, 29(June (15_suppl)):6631.
20. Herman S.E.M., Farooqui M., Bezabhie R., Aue G., Wiestner A. In vivo effects of ibrutinib on BCR signaling, tumor cell activation and proliferation in blood and tissue-resident cells of chronic lymphocytic leukemia patients. ASH Annual Meeting Abstracts 2012, 120(November (21)):185.
21. Borghesi L., Milcarek C. From B cell to plasma cell: regulation of V(D)J recombination and antibody secretion. Immunol Res 2006, 36(1-3):27-32.
22. Yang J., Reth M. Oligomeric organization of the B-cell antigen receptor on resting cells. Nature 2010, 467(September (7314)):465-469.
23. Liu W., Meckel T., Tolar P., Sohn H.W., Pierce S.K. Antigen affinity discrimination is an intrinsic function of the B cell receptor. J Exp Med 2010, 207(May (5)):1095-1111.
24. Reth M. Antigen receptor tail clue. Nature 1989, 338(March (6214)):383-384.
25. Bezbradica J.S., Medzhitov R. Role of ITAM signaling module in signal integration. Curr Opin Immunol 2012, 24(February (1)):58-66.
26. Saijo K., Schmedt C., Su I.H., Karasuyama H., Lowell C.A., Reth M., et al. Essential role of Src-family protein tyrosine kinases in NF-kappaB activation during B cell development. Nat Immunol 2003, 4(March (3)):274-279.
27. Nishizumi H., Taniuchi I., Yamanashi Y., Kitamura D., Ilic D., Mori S., et al. Impaired proliferation of peripheral B cells and indication of autoimmune disease in lyn-deficient mice. Immunity 1995, 3(November (5)):549-560.
28. Hibbs M.L., Tarlinton D.M., Armes J., Grail D., Hodgson G., Maglitto R., et al. Multiple defects in the immune system of Lyn-deficient mice, culminating in autoimmune disease. Cell 1995, 83(October (2)):301-311.
29. Hantschel O., Rix U., Schmidt U., Burckstummer T., Kneidinger M., Schutze G., et al. The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib. Proc Natl Acad Sci USA 2007, 104(August (33)):13283-13288.
30. Shi H., Zhang C.J., Chen G.Y., Yao S.Q. Cell-based proteome profiling of potential dasatinib targets by use of affinity-based probes. J Am Chem Soc 2012, 134(February (6)):3001-3014.
31. Ten H.E., Scielzo C., Bertilaccio M.T., Scarfo L., Apollonio B., Barbaglio F., et al. Targeting the LYN/HS1 signaling axis in chronic lymphocytic leukemia. Blood 2013, 121(March (12)):2264-2273.
32. Davis R.E., Ngo V.N., Lenz G., Tolar P., Young R.M., Romesser P.B., et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 2010, 463(January (7277)):88-92.
33. Amrein P.C., Attar E.C., Takvorian T., Hochberg E.P., Ballen K.K., Leahy K.M., et al. Phase II study of dasatinib in relapsed or refractory chronic lymphocytic leukemia. Clin Cancer Res 2011, 17(May (9)):2977-2986.
34. Mocsai A., Ruland J., Tybulewicz V.L. The SYK tyrosine kinase: a crucial player in diverse biological functions. Nat Rev Immunol 2010, 10(June (6)):387-402.
35. Orchard J.A., Ibbotson R.E., Davis Z., Wiestner A., Rosenwald A., Thomas P.W., et al. ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. Lancet 2004, 363(January (9403)):105-111.
36. Cheng A.M., Rowley B., Pao W., Hayday A., Bolen J.B., Pawson T. Syk tyrosine kinase required for mouse viability and B-cell development. Nature 1995, 378(November (6554)):303-306.
37. Turner M., Mee P.J., Costello P.S., Williams O., Price A.A., Duddy L.P., et al. Perinatal lethality and blocked B-cell development in mice lacking the tyrosine kinase Syk. Nature 1995, 378(November (6554)):298-302.
38. Rowley R.B., Burkhardt A.L., Chao H.G., Matsueda G.R., Bolen J.B. Syk protein-tyrosine kinase is regulated by tyrosine-phosphorylated Ig alpha/Ig beta immunoreceptor tyrosine activation motif binding and autophosphorylation. J Biol Chem 1995, 270(May (19)):11590-11594.
39. Efremov D.G., Laurenti L. The Syk kinase as a therapeutic target in leukemia and lymphoma. Expert Opin Investig Drugs 2011, 20(May (5)):623-636.
40. Herman S.E., Barr P.M., McAuley E.M., Liu D., Wiestner A., Friedberg J.W. Fostamatinib inhibits B-cell receptor signaling, cellular activation and tumor proliferation in patients with relapsed and refractory chronic lymphocytic leukemia. Leukemia 2013, February.
41. Genovese M.C., Kavanaugh A., Weinblatt M.E., Peterfy C., DiCarlo J., White M.L., et al. An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents. Arthritis Rheum 2011, 63(February (2)):337-345.
42. Hoellenriegel J., Coffey G.P., Sinha U., Pandey A., Sivina M., Ferrajoli A., et al. Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration. Leukemia 2012, 26(July (7)):1576-1583.
43. So L., Fruman D.A. PI3K signalling in B- and T-lymphocytes: new developments and therapeutic advances. Biochem J 2012, 442(March (3)):465-481.
44. Baracho G.V., Miletic A.V., Omori S.A., Cato M.H., Rickert R.C. Emergence of the PI3-kinase pathway as a central modulator of normal and aberrant B cell differentiation. Curr Opin Immunol 2011, 23(April (2)):178-183.
45. Srinivasan L., Sasaki Y., Calado D.P., Zhang B., Paik J.H., DePinho R.A., et al. PI3 kinase signals BCR-dependent mature B cell survival. Cell 2009, 139(October (3)):573-586.
46. Ramadani F., Bolland D.J., Garcon F., Emery J.L., Vanhaesebroeck B., Corcoran A.E., et al. The PI3K isoforms p110alpha and p110delta are essential for pre-B cell receptor signaling and B cell development. Sci Signal 2010, 3(134):ra60.
47. Lemmon M.A. Membrane recognition by phospholipid-binding domains. Nat Rev Mol Cell Biol 2008, 9(February (2)):99-111.
48. Ghosh A.K., Secreto C.R., Knox T.R., Ding W., Mukhopadhyay D., Kay N.E. Circulating microvesicles in B-cell chronic lymphocytic leukemia can stimulate marrow stromal cells: implications for disease progression. Blood 2010, 115(March (9)):1755-1764.
49. Ghosh A.K., Secreto C., Boysen J., Sassoon T., Shanafelt T.D., Mukhopadhyay D., et al. The novel receptor tyrosine kinase Axl is constitutively active in B-cell chronic lymphocytic leukemia and acts as a docking site of nonreceptor kinases: implications for therapy. Blood 2011, 117(February (6)):1928-1937.
50. Oellerich T., Bremes V., Neumann K., Bohnenberger H., Dittmann K., Hsiao H.H., et al. The B-cell antigen receptor signals through a preformed transducer module of SLP65 and CIN85. EMBO J 2011, 30(August (17)):3620-3634.
51. Miyazaki A., Yogosawa S., Murakami A., Kitamura D. Identification of CMTM7 as a transmembrane linker of BLNK and the B-cell receptor. PLoS ONE 2012, 7(2):e31829.
52. Gupta N., Scharenberg A.M., Fruman D.A., Cantley L.C., Kinet J.P., Long E.O. The SH2 domain-containing inositol 5'-phosphatase (SHIP) recruits the p85 subunit of phosphoinositide 3-kinase during FcgammaRIIb1-mediated inhibition of B cell receptor signaling. J Biol Chem 1999, 274(March (11)):7489-7494.
53. Hendriks R.W., Bredius R.G., Pike-Overzet K., Staal F.J. Biology and novel treatment options for XLA, the most common monogenetic immunodeficiency in man. Expert Opin Ther Targets 2011, 15(August (8)):1003-1021.
54. BRUTON OC Agammaglobulinemia. Pediatrics 1952, 9(June (6)):722-728.
55. Humphries L.A., Dangelmaier C., Sommer K., Kipp K., Kato R.M., Griffith N., et al. Tec kinases mediate sustained calcium influx via site-specific tyrosine phosphorylation of the phospholipase Cgamma Src homology 2-Src homology 3 linker. J Biol Chem 2004, 279(September (36)):37651-37661.
56. Murayama K., Kato-Murayama M., Mishima C., Akasaka R., Shirouzu M., Fukui Y., et al. Crystal structure of the Bruton's tyrosine kinase PH domain with phosphatidylinositol. Biochem Biophys Res Commun 2008, 377(December (1)):23-28.
57. Buggy J.J., Elias L. Bruton tyrosine kinase (BTK) and its role in B-cell malignancy. Int Rev Immunol 2012, 31(April (2)):119-132.
58. Honigberg L.A., Smith A.M., Sirisawad M., Verner E., Loury D., Chang B., et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci USA 2010, 107(July (29)):13075-13080.
59. Sharma S., Orlowski G., Song W. Btk regulates B cell receptor-mediated antigen processing and presentation by controlling actin cytoskeleton dynamics in B cells. J Immunol 2009, 182(January (1)):329-339.
60. Saijo K., Mecklenbrauker I., Santana A., Leitger M., Schmedt C., Tarakhovsky A. Protein kinase C beta controls nuclear factor kappaB activation in B cells through selective regulation of the IkappaB kinase alpha. J Exp Med 2002, 195(June (12)):1647-1652.
61. de Gorter D.J., Beuling E.A., Kersseboom R., Middendorp S., van Gils J.M., Hendriks R.W., et al. Bruton's tyrosine kinase and phospholipase Cgamma2 mediate chemokine-controlled B cell migration and homing. Immunity 2007, 26(January (1)):93-104.
62. Giles F.J., Albitar M. Mammalian target of rapamycin as a therapeutic target in leukemia. Curr Mol Med 2005, 5(November (7)):653-661.
63. Decker T., Hipp S., Ringshausen I., Bogner C., Oelsner M., Schneller F., et al. G1 arrest in cycling B-CLL cells is associated with reduced expression of cyclin D3, cyclin E, cyclin A, and survivin. Blood 2003, 101(January (1)):278-285.
64. Douros J., Suffness M. New antitumor substances of natural origin. Cancer Treat Rev 1981, 8(March (1)):63-87.
65. Heitman J., Movva N.R., Hall M.N. Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science 1991, 253(August (5022)):905-909.
66. Laplante M., Sabatini D.M. mTOR signaling in growth control and disease. Cell 2012, 149(April (2)):274-293.
67. Decker T., Sandherr M., Goetze K., Oelsner M., Ringshausen I., Peschel C. A pilot trial of the mTOR (mammalian target of rapamycin) inhibitor RAD001 in patients with advanced B-CLL. Ann Hematol 2009, 88(March (3)):221-227.
68. Zent C.S., LaPlant B.R., Johnston P.B., Call T.G., Habermann T.M., Micallef I.N., et al. The treatment of recurrent/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) with everolimus results in clinical responses and mobilization of CLL cells into the circulation. Cancer 2010, 116(May (9)):2201-2207.
69. Witzig T.E., Geyer S.M., Ghobrial I., Inwards D.J., Fonseca R., Kurtin P., et al. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol 2005, 23(August (23)):5347-5356.
70. Smith S.M., van B.K., Karrison T., Dancey J., McLaughlin P., Younes A., et al. Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: the University of Chicago phase II consortium. J Clin Oncol 2010, 28(November (31)):4740-4746.
71. Renner C., Zinzani P.L., Gressin R., Klingbiel D., Dietrich P.Y., Hitz F., et al. A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma. Haematologica 2012, 97(July (7)):1085-1091.
72. Witzig T.E., Reeder C.B., LaPlant B.R., Gupta M., Johnston P.B., Micallef I.N., et al. A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma. Leukemia 2011, 25(February (2)):341-347.
73. Liu W., Won S.H., Tolar P., Meckel T., Pierce S.K. Antigen-induced oligomerization of the B cell receptor is an early target of Fc gamma RIIB inhibition. J Immunol 2010, 184(February (4)):1977-1989.
74. Chaturvedi A., Martz R., Dorward D., Waisberg M., Pierce S.K. Endocytosed BCRs sequentially regulate MAPK and Akt signaling pathways from intracellular compartments. Nat Immunol 2011, 12(November (11)):1119-1126.
75. O'Neill S.K., Getahun A., Gauld S.B., Merrell K.T., Tamir I., Smith M.J., et al. Monophosphorylation of CD79a and CD79b ITAM motifs initiates a SHIP-1 phosphatase-mediated inhibitory signaling cascade required for B cell anergy. Immunity 2011, 35(November (5)):746-756.
76. Adachi T., Wienands J., Tsubata T., Kurosaki T. Interdomain A is crucial for ITAM-dependent and -independent regulation of Syk. Biochem Biophys Res Commun 2007, 364(December (1)):111-117.
77. Yarkoni Y., Getahun A., Cambier J.C. Molecular underpinning of B-cell anergy. Immunol Rev 2010, 237(September (1)):249-263.
78. Ysebaert L., Morschhauser F. Enzastaurin hydrochloride for lymphoma: reassessing the results of clinical trials in light of recent advances in the biology of B-cell malignancies. Expert Opin Investig Drugs 2011, 20(August (8)):1167-1174.
79. Liffraud C., Quillet-Mary A., Fournie J.J., Laurent G., Ysebaert L. Protein phosphatase-2A activation is a critical step for enzastaurin activity in chronic lymphoid leukemia cells. Leukemia Lymphoma 2012, 53(May (5)):966-972.
80. Holler C., Pinon J.D., Denk U., Heyder C., Hofbauer S., Greil R., et al. PKCbeta is essential for the development of chronic lymphocytic leukemia in the TCL1 transgenic mouse model: validation of PKCbeta as a therapeutic target in chronic lymphocytic leukemia. Blood 2009, 113(March (12)):2791-2794.
81. Lutzny G., Kocher T., Schmidt-Supprian M., Rudelius M., Klein-Hitpass L., Finch A.J., et al. Protein kinase c-beta-dependent activation of NF-kappaB in stromal cells is indispensable for the survival of chronic lymphocytic leukemia B cells in vivo. Cancer Cell 2013, 23(January (1)):77-92.
82. Chan W., Schaffer T.B., Pomerantz J.L. A quantitative signaling screen identifies CARD11 mutations in the CARD and LATCH domains that induce Bcl10 ubiquitination and human lymphoma cell survival. Mol Cell Biol 2013, 33(January (2)):429-443.
83. Zhou H., Wertz I., O'Rourke K., Ultsch M., Seshagiri S., Eby M., et al. Bcl10 activates the NF-kappaB pathway through ubiquitination of NEMO. Nature 2004, 427(January (6970)):167-171.
84. Everett P.C., Meyers J.A., Makkinje A., Rabbi M., Lerner A. Preclinical assessment of curcumin as a potential therapy for B-CLL. Am J Hematol 2007, 82(January (1)):23-30.
85. Fabre C., Mimura N., Bobb K., Kong S.Y., Gorgun G., Cirstea D., et al. Dual inhibition of canonical and noncanonical NF-kappaB pathways demonstrates significant antitumor activities in multiple myeloma. Clin Cancer Res 2012, 18(September (17)):4669-4681.
86. Roberts A.W., Seymour J.F., Brown J.R., Wierda W.G., Kipps T.J., Khaw S.L., et al. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol 2012, 30(February (5)):488-496.
87. Tudhope S.J., Mulligan E.A., Hunter J.E., Summerfield G.P., Marshall S., Wallis J., et al. P B S-1086, a "Pan-Rel" inhibitor, decreases viability of chronic lymphocytic leukemia cells. ASH Annual Meeting Abstracts 2012, 120(November (21)):867.
88. Marcucci F., Mele A. Hepatitis viruses and non-Hodgkin lymphoma: epidemiology, mechanisms of tumorigenesis, and therapeutic opportunities. Blood 2011, 117(February (6)):1792-1798.
89. Gisbert J.P., Garcia-Buey L., Pajares J.M., Moreno-Otero R. Systematic review: regression of lymphoproliferative disorders after treatment for hepatitis C infection. Aliment Pharmacol Ther 2005, 21(March (6)):653-662.
90. Parsonnet J., Hansen S., Rodriguez L., Gelb A.B., Warnke R.A., Jellum E., et al. Helicobacter pylori infection and gastric lymphoma. N Engl J Med 1994, 330(May (18)):1267-1271.
91. Mueller A., O'rourke J., Chu P., Chu A., Dixon M.F., Bouley D.M., et al. The role of antigenic drive and tumor-infiltrating accessory cells in the pathogenesis of helicobacter-induced mucosa-associated lymphoid tissue lymphoma. Am J Pathol 2005, 167(September (3)):797-812.
92. Fais F., Ghiotto F., Hashimoto S., Sellars B., Valetto A., Allen S.L., et al. Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. J Clin Invest 1998, 102(October (8)):1515-1525.
93. Tobin G., Thunberg U., Karlsson K., Murray F., Laurell A., Willander K., et al. Subsets with restricted immunoglobulin gene rearrangement features indicate a role for antigen selection in the development of chronic lymphocytic leukemia. Blood 2004, 104(November (9)):2879-2885.
94. Messmer B.T., Albesiano E., Efremov D.G., Ghiotto F., Allen S.L., Kolitz J., et al. Multiple distinct sets of stereotyped antigen receptors indicate a role for antigen in promoting chronic lymphocytic leukemia. J Exp Med 2004, 200(August (4)):519-525.
95. Chiorazzi N., Rai K.R., Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med 2005, 352(February (8)):804-815.
96. Chen L., Apgar J., Huynh L., Dicker F., Giago-McGahan T., Rassenti L., et al. ZAP-70 directly enhances IgM signaling in chronic lymphocytic leukemia. Blood 2005, 105(March (5)):2036-2041.
97. Gobessi S., Laurenti L., Longo P.G., Sica S., Leone G., Efremov D.G. ZAP-70 enhances B-cell-receptor signaling despite absent or inefficient tyrosine kinase activation in chronic lymphocytic leukemia and lymphoma B cells. Blood 2007, 109(March (5)):2032-2039.
98. Herishanu Y., Perez-Galan P., Liu D., Biancotto A., Pittaluga S., Vire B., et al. The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood 2011, 117(January (2)):563-574.
99. Chu C.C., Catera R., Hatzi K., Yan X.J., Zhang L., Wang X.B., et al. Chronic lymphocytic leukemia antibodies with a common stereotypic rearrangement recognize nonmuscle myosin heavy chain IIA. Blood 2008, 112(December (13)):5122-5129.
100. Lanemo M.A., Hellqvist E., Sidorova E., Soderberg A., Baxendale H., Dahle C., et al. A new perspective: molecular motifs on oxidized LDL, apoptotic cells, and bacteria are targets for chronic lymphocytic leukemia antibodies. Blood 2008, 111(April (7)):3838-3848.
101. Steininger C., Widhopf G.F., Ghia E.M., Morello C.S., Vanura K., Sanders R., et al. Recombinant antibodies encoded by IGHV1-69 react with pUL32, a phosphoprotein of cytomegalovirus and B-cell superantigen. Blood 2012, 119(March (10)):2293-2301.
102. Hoogeboom R., van Kessel K.P., Hochstenbach F., Wormhoudt T.A., Reinten R.J., Wagner K., et al. A mutated B cell chronic lymphocytic leukemia subset that recognizes and responds to fungi. J Exp Med 2013, 210(January (1)):59-70.
103. Mockridge C.I., Potter K.N., Wheatley I., Neville L.A., Packham G., Stevenson F.K. Reversible anergy of sIgM-mediated signaling in the two subsets of CLL defined by VH-gene mutational status. Blood 2007, 109(May (10)):4424-4431.
104. Muzio M., Apollonio B., Scielzo C., Frenquelli M., Vandoni I., Boussiotis V., et al. Constitutive activation of distinct BCR-signaling pathways in a subset of CLL patients: a molecular signature of anergy. Blood 2008, 112(July (1)):188-195.
105. Corcos D., Osborn M.J., Matheson L.S. B-cell receptors and heavy chain diseases: guilty by association?. Blood 2011, 117(June (26)):6991-6998.
106. Binder M., Muller F., Jackst A., Lechenne B., Pantic M., Bacher U., et al. B-cell receptor epitope recognition correlates with the clinical course of chronic lymphocytic leukemia. Cancer 2011, 117(May (9)):1891-1900.
107. Guarini A., Chiaretti S., Tavolaro S., Maggio R., Peragine N., Citarella F., et al. BCR ligation induced by IgM stimulation results in gene expression and functional changes only in IgV H unmutated chronic lymphocytic leukemia (CLL) cells. Blood 2008, 112(August (3)):782-792.
108. Burger J.A. Inhibiting B-cell receptor signaling pathways in chronic lymphocytic leukemia. Curr Hematol Malig Rep 2012, 7(March (1)):26-33.
109. Efremov D.G., Wiestner A., Laurenti L., Novel Agents Emerging strategies for targeting the B-cell receptor pathway in CLL. Mediterr J Hematol Infect Dis 2012, 4(1):e2012067.
110. Wiestner A. Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia. Blood 2012, 120(December (24)):4684-4691.
111. Hadzidimitriou A., Agathangelidis A., Darzentas N., Murray F., Delfau-Larue M.H., Pedersen L.B., et al. Is there a role for antigen selection in mantle cell lymphoma? Immunogenetic support from a series of 807 cases. Blood 2011, 118(September (15)):3088-3095.
112. Perez-Galan P., Dreyling M., Wiestner A. Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era. Blood 2011, 117(January (1)):26-38.
113. Varettoni M., Zibellini S., Capello D., Arcaini L., Rossi D., Pascutto C., et al. Clues to pathogenesis of Waldenstrom macroglobulinemia and immunoglobulin M monoclonal gammopathy of undetermined significance provided by analysis of immunoglobulin heavy chain gene rearrangement and clustering of B-cell receptors. Leukemia Lymphoma 2013, April.
114. Arons E., Roth L., Sapolsky J., Suntum T., Stetler-Stevenson M., Kreitman R.J. Evidence of canonical somatic hypermutation in hairy cell leukemia. Blood 2011, 117(May (18)):4844-4851.
115. Forconi F., Cencini E., Sicuranza A., Sozzi E., Lauria F. Molecular insight into the biology and clinical course of hairy cell leukemia utilizing immunoglobulin gene analysis. Leukemia Lymphoma 2011, 52(January (1)):15-23.
116. Thelander E.F., Rosenquist R. Molecular genetic characterization reveals new subsets of mantle cell lymphoma. Leukemia Lymphoma 2008, 49(June (6)):1042-1049.
117. Coelho V., Krysov S., Ghaemmaghami A.M., Emara M., Potter K.N., Johnson P., et al. Glycosylation of surface Ig creates a functional bridge between human follicular lymphoma and microenvironmental lectins. Proc Natl Acad Sci USA 2010, 107(October (43)):18587-18592.
118. Lenz G., Nagel I., Siebert R., Roschke A.V., Sanger W., Wright G.W., et al. Aberrant immunoglobulin class switch recombination and switch translocations in activated B cell-like diffuse large B cell lymphoma. J Exp Med 2007, 204(March (3)):633-643.
119. Staudt L.M. A closer look at follicular lymphoma. N Engl J Med 2007, 356(February (7)):741-742.
120. Vaandrager J.W., Schuuring E., Kluin-Nelemans H.C., Dyer M.J., Raap A.K., Kluin P.M. DNA fiber fluorescence in situ hybridization analysis of immunoglobulin class switching in B-cell neoplasia: aberrant CH gene rearrangements in follicle center-cell lymphoma. Blood 1998, 92(October (8)):2871-2878.
121. Zuckerman N.S., McCann K.J., Ottensmeier C.H., Barak M., Shahaf G., Edelman H., et al. Ig gene diversification and selection in follicular lymphoma, diffuse large B cell lymphoma and primary central nervous system lymphoma revealed by lineage tree and mutation analyses. Int Immunol 2010, 22(November (11)):875-887.
122. Kloo B., Nagel D., Pfeifer M., Grau M., Duwel M., Vincendeau M., et al. Critical role of PI3K signaling for NF-kappaB-dependent survival in a subset of activated B-cell-like diffuse large B-cell lymphoma cells. Proc Natl Acad Sci USA 2011, 108(January (1)):272-277.
123. Compagno M., Lim W.K., Grunn A., Nandula S.V., Brahmachary M., Shen Q., et al. Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature 2009, 459(June (7247)):717-721.
124. Maes B., Demunter A., Peeters B., De Wolf-Peeters C. BCL10 mutation does not represent an important pathogenic mechanism in gastric MALT-type lymphoma, and the presence of the API2-MLT fusion is associated with aberrant nuclear BCL10 expression. Blood 2002, 99(February (4)):1398-1404.
125. Willis T.G., Jadayel D.M., Du M.Q., Peng H., Perry A.R., Abdul-Rauf M., et al. Bcl10 is involved in t(1;14)(p22;q32) of MALT B cell lymphoma and mutated in multiple tumor types. Cell 1999, 96(January (1)):35-45.
126. Dierlamm J., Baens M., Wlodarska I., Stefanova-Ouzounova M., Hernandez J.M., Hossfeld D.K., et al. The apoptosis inhibitor gene API2 and a novel 18q gene, MLT, are recurrently rearranged in the t(11;18)(q21;q21) associated with mucosa-associated lymphoid tissue lymphomas. Blood 1999, 93(June (11)):3601-3609.
127. McAllister-Lucas L.M., Baens M., Lucas P.C. MALT1 protease: a new therapeutic target in B lymphoma and beyond?. Clin Cancer Res 2011, 17(November (21)):6623-6631.
128. Liu H., Ruskon-Fourmestraux A., Lavergne-Slove A., Ye H., Molina T., Bouhnik Y., et al. Resistance of t(11;18) positive gastric mucosa-associated lymphoid tissue lymphoma to Helicobacter pylori eradication therapy. Lancet 2001, 357(January (9249)):39-40.
129. Ye H., Gong L., Liu H., Ruskone-Fourmestraux A., de Jong D., Pileri S., et al. Strong BCL10 nuclear expression identifies gastric MALT lymphomas that do not respond to H. pylori eradication. Gut 2006, 55(January (1)):137-138.
130. Schmitz R., Young R.M., Ceribelli M., Jhavar S., Xiao W., Zhang M., et al. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature 2012, 490(October (7418)):116-120.
131. Sander S., Calado D.P., Srinivasan L., Kochert K., Zhang B., Rosolowski M., et al. Synergy between PI3K signaling and MYC in Burkitt lymphomagenesis. Cancer Cell 2012, 22(August (2)):167-179.
132. Miletic A.V., Anzelon-Mills A.N., Mills D.M., Omori S.A., Pedersen I.M., Shin D.M., et al. Coordinate suppression of B cell lymphoma by PTEN and SHIP phosphatases. J Exp Med 2010, 207(October (11)):2407-2420.
133. Abubaker J., Bavi P.P., Al-Harbi S., Siraj A.K., Al-Dayel F., Uddin S., et al. PIK3CA mutations are mutually exclusive with PTEN loss in diffuse large B-cell lymphoma. Leukemia 2007, 21(November (11)):2368-2370.
134. Lenz G., Wright G.W., Emre N.C., Kohlhammer H., Dave S.S., Davis R.E., et al. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci USA 2008, 105(September (36)):13520-13525.
135. Hofmann B.T., Jucker M. Activation of PI3K/Akt signaling by n-terminal SH2 domain mutants of the p85alpha regulatory subunit of PI3K is enhanced by deletion of its c-terminal SH2 domain. Cell Signal 2012, 24(October (10)):1950-1954.
136. Lannutti B.J., Meadows S.A., Herman S.E., Kashishian A., Steiner B., Johnson A.J., et al. CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood 2011, 117(January (2)):591-594.
137. Rudelius M., Pittaluga S., Nishizuka S., Pham T.H., Fend F., Jaffe E.S., et al. Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma. Blood 2006, 108(September (5)):1668-1676.
138. Herman S.E., Gordon A.L., Wagner A.J., Heerema N.A., Zhao W., Flynn J.M., et al. Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood 2010, 116(September (12)):2078-2088.
139. Hoellenriegel J., Meadows S.A., Sivina M., Wierda W.G., Kantarjian H., Keating M.J., et al. The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood 2011, 118(September (13)):3603-3612.
140. Burger J.A., Quiroga M.P., Hartmann E., Burkle A., Wierda W.G., Keating M.J., et al. High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation. Blood 2009, 113(March (13)):3050-3058.
141. Hallek M., Cheson B.D., Catovsky D., Caligaris-Cappio F., Dighiero G., Dohner H., et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008, 111(June (12)):5446-5456.
142. Furman R.R., Byrd J.C., Brown J.R., Coutre S.E., Benson D.M., Wagner-Johnston N.D., et al. CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110{delta}, demonstrates clinical activity and pharmacodynamic effects in patients with relapsed or refractory chronic lymphocytic leukemia. ASH Annual Meeting Abstracts 2010, 116(November (21)):55.
143. Cheson B.D., Byrd J.C., Rai K.R., Kay N.E., O'Brien S.M., Flinn I.W., et al. Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia. J Clin Oncol 2012, 30(August (23)):2820-2822.
144. Coutre S.E., Leonard J.P., Furman R.R., Barrientos J.C., De Vos S., Flinn I.W., et al. Combinations of the selective phosphatidylinositol 3-kinase-delta (PI3Kdelta) inhibitor GS-1101 (CAL-101) with rituximab and/or bendamustine are tolerable and highly active in patients with relapsed or refractory chronic lymphocytic leukemia (CLL): results from a phase I study. ASH Annual Meeting Abstracts 2012, 120(November (21)):191.
145. Furman R.R., Barrientos J.C., Sharman J.P., De Vos S., Leonard J., Coutre S.E., et al. A phase I/II study of the selective phosphatidylinositol 3-kinase-delta (PI3K{delta}) inhibitor, GS-1101 (CAL-101), with ofatumumab in patients with previously treated chronic lymphocytic leukemia (CLL). ASCO Meeting Abstracts 2012, 30(May (15_suppl)):6518.
146. Niedermeier M., Hennessy B.T., Knight Z.A., Henneberg M., Hu J., Kurtova A.V., et al. Isoform-selective phosphoinositide 3'-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach. Blood 2009, 113(May (22)):5549-5557.
147. Chapman C.M., Sun X., Roschewski M., Aue G., Farooqui M., Stennett L., et al. ON 01910.Na is selectively cytotoxic for chronic lymphocytic leukemia cells through a dual mechanism of action involving PI3K/AKT inhibition and induction of oxidative stress. Clin Cancer Res 2012, 18(April (7)):1979-1991.
148. Brown J.R., Davids M.S., Rodon J., Abrisqueta P., DeCillis A.P., Rockich K., Egile C., et al. Phase I trial of SAR245408 (S08), a pan-phosphatidylinositol 3 kinase (PI3K) inhibitor, in patients with chronic lymphocytic leukemia (CLL) and lymphoma. ASH Annual Meeting Abstracts 2011, 118(November (21)):2683.
149. Friedman D.R., Lanasa M.C., Brander D.M., Allgood S.D., Davis E.D., Miskin H., et al. Comparison of the PI3K-{delta} inhibitors TGR1202 and GS-1101 in inducing cytotoxicity and inhibiting phosphorylation of Akt in CLL cells in vitro. ASH Annual Meeting Abstracts 2012, 120(November (21)):3914.
150. O'Farrell M., Ventura R., Tai A., Tyner J.W., Loriaux M.M., Mahadevan D., et al. Preclinical characterization of PWT143, a novel selective and potent phosphatidylinositol 3-kinase delta (PI3K delta) inhibitor with ex-vivo activity in hematologic malignancies. ASH Annual Meeting Abstracts 2012, 120(November (21)):2907.
151. Vanhaesebroeck B., Guillermet-Guibert J., Graupera M., Bilanges B. The emerging mechanisms of isoform-specific PI3K signalling. Nat Rev Mol Cell Biol 2010, 11(May (5)):329-341.
152. Wang M.L., Rule S., Martin P., Goy A., Auer R., Kahl B.S., et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 2013, June.
153. Wilson W.H., Gerecitano J.F., Goy A., De Vos S., Kenkre V.P., Barr P.M., et al. The Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib (PCI-32765), has preferential activity in the abc subtype of relapsed/refractory de novo diffuse large B-cell lymphoma (DLBCL): interim results of a multicenter, open-label, phase 2 study. ASH Annual Meeting Abstracts 2012, 120(November (21)):686.
154. Pan Z., Scheerens H., Li S.J., Schultz B.E., Sprengeler P.A., Burrill L.C., et al. Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase. ChemMedChem 2007, 2(January (1)):58-61.
155. de Rooij M.F., Kuil A., Geest C.R., Eldering E., Chang B.Y., Buggy J.J., et al. The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. Blood 2012, 119(March (11)):2590-2594.
156. Herman S.E., Farooqui M., Bezabhie R., Aue G., Wiestner A. In vivo effects of ibrutinib on BCR signaling, tumor cell activation and proliferation in blood and tissue-resident cells of chronic lymphocytic leukemia patients. ASH Annual Meeting Abstracts 2012.
157. Herman S.E., Gordon A.L., Hertlein E., Ramanunni A., Zhang X., Jaglowski S., et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood 2011, 117(June (23)):6287-6296.
158. Ponader S., Chen S.S., Buggy J.J., Balakrishnan K., Gandhi V., Wierda W.G., et al. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood 2012, 119(February (5)):1182-1189.
159. Kim E., Koehrer S., Rosin N.Y., Thomas D.A., Ravandi F., Kornblau S.M., et al. Activity of Bruton's tyrosine kinase (BTK) inhibitor ibrutinib (PCI-32765) in B-cell acute lymphoblastic leukemia (B-ALL). ASH Annual Meeting Abstracts 2012, 120(November (21)):2569.
160. Sivina M., Kreitman R.J., Arons E., Buggy J.J., Ravandi F., Burger J.A. Bruton's tyrosine kinase (BTK) inhibitor ibrutinib (PCI-32765) blocks hairy cell leukemia (HCL) survival, proliferation, and BCR signaling: a new therapeutic approach for HCL. ASH Annual Meeting Abstracts 2012, 120(November (21)):1802.
161. Fowler N.H., Advani R.H., Sharman J., Smith S.M., McGreivy J., Kunkel L., et al. The Bruton's tyrosine kinase inhibitor ibrutinib (PCI-32765) is active and tolerated in relapsed follicular lymphoma. ASH Annual Meeting Abstracts 2012, 120(November (21)):156.
162. Wiestner A., Farooqui M., Valdez J., Jones J., Marti G.E., Arthur D.C., et al. Single agent ibrutinib (PCI-32765) is highly effective in chronic lymphocytic leukemia patients with 17p deletion. Hematol Oncol 2013, 31(June (S1)):96-150.
163. Jaglowski S.M., Jones J.A., Flynn J.M., Andritsos L.A., Maddocks K.J., Blum K.A., et al. A phase Ib/II study evaluating activity and tolerability of BTK inhibitor PCI-32765 and ofatumumab in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and related diseases. ASCO Meeting Abstracts 2012, 30(May (15_suppl)):6508.
164. O'Brien S.M., Barrientos J.C., Flinn I.W., Barr P.M., Burger J.A., Navarro T., et al. Combination of the Bruton's tyrosine kinase (BTK) inhibitor PCI-32765 with bendamustine (B)/rituximab (R) (BR) in patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): Interim results of a phase Ib/II study. ASCO Meeting Abstracts 2012, 30(May (15_suppl)):6515.
165. Burger J.A., Keating M.J., Wierda W.G., Hoellenriegel J., Ferrajoli A., Faderl S., et al. The Btk inhibitor ibrutinib (PCI-32765) in combination with rituximab is well tolerated and displays profound activity in high-risk chronic lymphocytic leukemia (CLL) patients. ASH Annual Meeting Abstracts 2012, 120(November (21)):187.
166. Brown J.R., Sharman J.P., Harb W.A., Kelly K.R., Schreeder M.T., Sweetenham J.W., et al. Phase Ib trial of AVL-292, a covalent inhibitor of Bruton's tyrosine kinase (Btk), in chronic lymphocytic leukemia (CLL) and B-non-Hodgkin lymphoma (B-NHL). ASCO Meeting Abstracts 2012, 30(May (15_suppl)):8032.
167. Brown J.R., Harb W.A., Sharman J., Hill B., Ma S., Miller T.P., et al. Phase 1 study of single agent CC-292, a highly selective Bruton's tyrosine kinase (BTK) inhibitor, in relapsed/refractory chronic lymphocytic leukemia (CLL) and B-cell Non-Hodgkin lymphoma (B-NHL). Haematologica 2013, 98(June (s1)):217.
168. Robak T., Robak E. Tyrosine kinase inhibitors as potential drugs for B-cell lymphoid malignancies and autoimmune disorders. Expert Opin Investig Drugs 2012, 21(July (7)):921-947.
169. Kahl B., Byrd J.C., Flinn I.W., Wagner-Johnston N., Spurgeon S., Benson D.M., et al. Clinical safety and activity in a phase 1 study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110{delta}, in patients with relapsed or refractory non-Hodgkin lymphoma. ASH Annual Meeting Abstracts 2010, 116(November (21)):1777.
170. Byrd J.C., Furman R.R., Coutre S.E., Flinn I.W., Burger J.A., Blum K.A., et al. The Bruton's tyrosine kinase (BTK) inhibitor ibrutinib (PCI-32765) promotes high response rate, durable remissions, and is tolerable in treatment naïve (TN) and relapsed or refractory (RR) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) patients including patients with high-risk (HR) disease: new and updated results of 116 patients in a phase Ib/II study. ASH Annual Meeting Abstracts 2012.